GS-441524 (NeoFipronis) Package Insert and Instructions
GS-441524, marketed as NeoFipronis (Pronidesivir), is a groundbreaking oral medication specifically designed to treat Feline Infectious Peritonitis (FIP). FIP is a severe and often fatal disease caused by a mutated feline coronavirus, leading to symptoms such as anorexia, lethargy, fever, ascites, pleural effusion, lymphadenopathy, granulomatous inflammation, neurological damage, and uveitis. NeoFipronis has demonstrated remarkable efficacy in alleviating these symptoms and improving survival rates.
Product Overview
NeoFipronis (Pronidesivir) is the world's first FIP-specific oral treatment officially approved by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026. It bears a formal regulatory registration number, confirming its safety and efficacy. The active ingredient in NeoFipronis is GS-441524, a nucleoside analog with potent antiviral properties. Extensive research and clinical trials have validated its ability to inhibit feline coronavirus replication, providing an effective therapeutic option for FIP.
Key Features
NeoFipronis is a safe, non-invasive, fast-absorbing medication with rapid onset of action. It provides a well-tolerated treatment profile with minimal side effects. The medication's oral administration simplifies dosing and enhances compliance, making it suitable for long-term therapy. Its remarkable antiviral activity makes it a preferred choice for veterinarians addressing both classic and neurological or ocular forms of FIP.
Dosage and Administration
The recommended dosage is calculated based on the cat’s body weight—15 mg per kilogram (half a tablet). For cats with neurological or ocular involvement, the dosage can be increased to 30 mg per kilogram, but only under veterinary supervision and strict adherence to medical guidance. Administer NeoFipronis once daily, preferably on an empty stomach—either one hour before feeding or two hours after—ensuring optimal drug absorption.
Treatment Duration
A continuous treatment period of no less than 12 weeks is essential for achieving optimal outcomes. It is critical not to skip doses during this period, as inconsistent dosing may reduce effectiveness and lead to relapse. Regular monitoring of the cat’s clinical signs—including appetite, body temperature, activity level—and periodic blood tests for liver, kidney, and overall health status are vital during therapy.
Usage Precautions
While NeoFipronis is available as an over-the-counter medication, veterinary supervision is highly recommended to maximize safety and efficacy. The medication is for feline use only and should not be administered to humans. Proper storage in a cool, dry place away from direct sunlight ensures the integrity of the product. Always purchase NeoFipronis from official sources via the official website to verify authenticity and safety.
Warnings and Safety
NeoFipronis is generally well-tolerated, with minimal adverse effects reported. However, potential side effects such as mild gastrointestinal upset or transient changes in liver enzymes may occur. If any abnormal signs are observed, consult a veterinarian promptly. The medication should be used exclusively for treating FIP in cats and not for any other conditions or species.
Conclusion
NeoFipronis (Pronidesivir) stands out as a significant advancement in feline medicine, providing a safe, effective, and easy-to-administer oral treatment for FIP. Its proven antiviral potency, combined with its favorable safety profile, offers new hope for cats suffering from this devastating disease. For optimal results, follow dosage recommendations carefully, maintain regular veterinary check-ups, and purchase only through authorized channels.
Where to Buy
Visit the official NeoFipronis website to find authorized distributors and ensure genuine product quality. Always adhere to veterinary guidance when administering this medication to ensure the best possible outcome for your feline companion.
Note: This medication is intended solely for use in cats. Do not attempt to use or administer NeoFipronis to humans under any circumstances.
